![]() |
![]() |
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
(51) | INT.CL. | A61K 39/395 | (2006.01) |
A61K 45/06 | (2013.01) | ||
A61K 45/06 | (2006.01) | ||
C07K2317/76 | (2013.01) | ||
A61K 31/542 | (2006.01) | ||
A61K 31/542 | (2013.01) | ||
A61P 35/00 | (2006.01) | ||
A61P 35/00 | (2018.01) | ||
C07K 16/2827 | (2013.01) | ||
A61K 31/55 | (2013.01) | ||
C07K 16/2818 | (2013.01) | ||
A61K 39/3955 | (2013.01) |
(11) | Patento numeris | 3458091 |
(13) | Dokumento rūšis | T |
(96) | Europos patento paraiškos numeris | 17726073.4 |
Europos patento paraiškos padavimo data | 2017-05-16 | |
(97) | Europos patento paraiškos paskelbimo data | 2019-03-27 |
(45) | Paskelbimo apie Europos patento išdavimą data | 2021-11-17 |
(46) | Apibrėžties vertimo paskelbimo data |
(86) | Numeris | PCT/US2017/032790 |
Data | 2017-05-16 |
(87) | Numeris | WO 2017/200969 |
Data | 2017-11-23 |
(30) | Numeris | Data | Šalis |
201662339363 P | 2016-05-20 | US |
(72) |
BENDER, Mark Harrath , US
GAO, Hong , US
PATEL, Bharvin Kumar , US
|
(73) |
Eli Lilly and Company ,
Lilly Corporate Center, Indianapolis, IN 46285,
US
|
(54) | COMBINATION THERAPY WITH NOTCH AND PD-1 OR PD-L1 INHIBITORS |
COMBINATION THERAPY WITH NOTCH AND PD-1 OR PD-L1 INHIBITORS |